John Gutheil
Northwestern University
6 Papers
166 Citations
John Gutheil is an academic researcher from Northwestern University. The author has contributed to research in topics: Radioimmunotherapy & Rituximab. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
•Journal Article
A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
Mansoor N. Saleh,John Gutheil,Melvin R. Moore,Patty W. Bunch,June Butler,Lori A. Kunkel,Antonio J. Grillo-Lopez,Albert F. LoBuglio +7 more
TL;DR: A prospective pilot phase I/II clinical trial to evaluate the toxicity and response rate of the chimeric anti-CD20 monoclonal antibody, rituximab (Rituxan), in the treatment of patients with immune thrombocytopenic purpura, finding three of nine patients who have received ritUXimab at doses close to the full dose have shown an objective clinical response.
160
•Journal Article
Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a 90Y-labeled Anti-CD20 Monoclonal Antibody
Gregory A. Wiseman,Christine A. White,Thomas E. Witzig,Leo I. Gordon,Christos Emmanouilides,Andrew Raubitschek,Nalini Janakiraman,John Gutheil,Russell J. Schilder,Stewart Spies,Daniel H.S. Silverman,Antonio J. Grillo-Lopez +11 more
TL;DR: The chimeric monoclonal antibody Rituximab has now been approved by the United States Food and Drug Administration as a treatment for patients with relapsed or refractory, low-grade or follicular, B-cell NHL.
131
Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a 9~ Anti-CD20 Monoclonal Antibody 1
Gregory A. Wiseman,C.A. White,Thomas E. Witzig,Leo I. Gordon,Christos Emmanouilides,Andrew Raubitschek,Nalini Janakiraman,John Gutheil,Russell J. Schilder,Stewart Spies,Daniel H.S. Silverman,Antonio J. Grillo-L +11 more
- 01 Jan 1999
TL;DR: The chimeric monoclonal antibody Rituximab has now been approved by the United States Food and Drug Administration as a treatment for patients with relapsed or refractory, low-grade or follicular, B-cell NHL.
1
•Journal Article
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.
John Gutheil,Thomas N. Campbell,Paul R. Pierce,Jeffry D. Watkins,William D. Huse,David J. Bodkin,David A. Cheresh +6 more
TL;DR: At the doses and schedule studied, Vitaxin appears safe and potentially active, suggesting that vascular integrin alphavbeta3 represents a clinically relevant antiangiogenic target for prolonged cancer therapy.